Ayanth Theyver, Student at West Ranch High School, shared a post on LinkedIn:
“Frontline care for indolent B-cell lymphoma is evolving fast, and chemotherapy-free regimens are leading the way.
This MedNews Week | OncoDaily lecture features Dr. Paolo Strati, Associate Professor and Deputy Section Chief for Indolent B-cell Lymphomas at The University of Texas MD Anderson Cancer Center, walking through his Phase 2 data on AR² therapy (acalabrutinib plus lenalidomide plus rituximab) as a frontline non-chemotherapy regimen for follicular and marginal zone lymphoma.
A few themes that stood out:
- Novel frontline combinations are challenging the long-standing role of chemotherapy in indolent B-cell lymphoma treatment
- Targeting the tumor immune microenvironment may be key to improving both response depth and durability
- The field is moving toward treatment strategies that prioritize long-term disease control without sacrificing tolerability or quality of life
A must-watch for anyone following the future of lymphoma treatment, precision immunotherapy, and chemotherapy-free oncology.”